Smart trial one-year data demonstrates medtronic evolut™ tavr platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women

New data from largest head-to-head randomized control tavr trial demonstrates non-inferior clinical outcomes and superior valve performance for evolut tavr compared to sapien™ at one year dublin and atlanta , april 7, 2024 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (tavr), were presented as a late breaking clinical trial at the american college of cardiology annual scientific session and simultaneously published in the new england journal of medicine. the one-year results of the small annuli randomized to evolut or sapien (smart) trial in individuals with aortic stenosis (as) with small aortic annuli (saa) demonstrated noninferior clinical outcomes and superior valve performance as measured by bioprosthetic valve dysfunction performance for the evolut™ tavr platform compared to the sapien™ platform.
MDT Ratings Summary
MDT Quant Ranking